On past form I don't think the company will take undue risks to meet the options expiry date (thank goodness).
From memory I think proof of concept was originally scheduled for about the time the *last* batch of options expired early this year. Then there was the Origin promise of $9 million if proof of concept came about by last March.
Now we've got another batch of options due to expire and we're still waiting on the same sorts of milestones - and at best it looks like it will be touch and go again for anyone holding them.
But on the bright side I can't see any outrageous risks being taken. There aren't a lot of these options anyway so in the grand scheme not a lot to lose. And if things go the right way for them regarding the tests, they will be in a better position to raise capital anyway (and probably issue more options along the way).
RNE Price at posting:
92.0¢ Sentiment: Hold Disclosure: Held
